TTUHSC School of Medicine
HomeSchool of MedicineCell Biology & BiochemistryFaculty

Cancer Center

Reynolds

C. Patrick Reynolds, M.D., Ph.D.

Professor

M.D. - University of Texas Southwestern Medical School, Dallas, TX
Ph.D. Cell Biology - University of Texas at Austin
Curriculum Vitae

Professor of Cell Biology and Biochemistry, Internal Medicine, and Pediatrics
Cancer Center Director

Texas Tech University Health Sciences Center
3601 4th Street
Lubbock, Texas 79430
Phone: (806) 743-1558
patrick.reynolds@ttuhsc.edu


Research Interests

Developmental therapeutics of adult and pediatric cancers in both laboratory and clinical studies. Types of drugs studied include retinoids, "vitamin A derivatives" as tumor-selective differentiation or cytotoxic agents and drugs such as depletors of glutathione or Bcl-2 inhibitors that overcome resistance to traditional cytotoxic agents. Other research identifies molecular mechanisms of drug resistance that may provide novel therapeutic targets in childhood and adult cancers, development of novel preclinical testing models for childhood and adult cancer drug development, and clinical trials testing novel therapeutic approaches for cancer.

To learn more, visit:

TTUHSC SOM Cancer Center Cancer.TTUHSC.edu
Children’s Oncology Group (COG) Cell Line and Xenograft Repository: www.COGcell.org
NCI PPTP In Vitro Drug Testing Lab www.PPTPinvitro.org
South Plains Oncology Consortium www.SPONC.org
Texas Cancer Cell Repository www.TXCCR.org
DrugPath Drug to Molecular Pathway matching database www.DrugPath.org
Texas Cancer Research Biobank www.TXCRB.org


Selected Publications

(From 198 peer-reviewed publications, H Index = 62)

  1. Tagde A, Singh H, Kang MH, Reynolds CP: Glutathione synthesis inhibitor buthionine sulfoximine synergized melphalan activity against preclinical models of multiple myeloma. Blood Cancer Journal, 18;4:e2292014 PMID:25036800 [PubMed]
  2. Shah ED, Fisch BMA, Arceci RJ, Buckley JD, Reaman GH, Sorensen PH, Triche TJ, Reynolds CP: DrugPath: A database for academic investigators to match oncology molecular targets with drugs in development. Cancer Chemotherapy & Pharmacology Epub ahead of print Mar 25, 2014. PMID:24663501 [PubMed]
  3. May WA, Grigoryan RS, Keshelava N, Cabral JD, Christensen LL, Jenabi J, Ji L, Lawlor ER, Reynolds CP: Characterization and drug resistance patterns of Ewing’s sarcoma family tumor cell lines. PLOS One Dec 2;8(12):e80060. doi: 10.1371/journal.pone.0080060, 2013. PMID: 24312454 [PubMed]
  4. Maurer BJ, Kang MH, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Villablanca JG, Czarnecki S, Beth Hasenauer B, Reynolds CP, Marachelian A: Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed neuroblastoma: A report from the NANT consortium. Pediatr Blood Cancer 60:1801-8, 2013. PMID: 23813912 [PubMed]
  5. Sausen M, Leary RJ, Wu J, Reynolds CP, Liu X, Maris J, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD: Genomic landscape of the childhood cancer neuroblastoma. Nature Genetics 45:12-17, 2013. [PubMed]
  6. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology 107:269-80, 2012. [PubMed]
  7. Villablanca JG. London WB, Naranjo A, McGrady MS, Ames MM Joel M. Reid JM, McGovern RM, Buhrow SA, Stranzinger JH, Kitchen BJ, Sondel PM, Parisi M, Shulkin B, Yanik GA, Cohn S, Reynolds CP: Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children’s Oncology Group NSC #374551; IND# 40294. Clinical Cancer Research 17:6858-6866, 2011. [PubMed]
  8. Fang H Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP: Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clinical Cancer Research 17:7093-104, 2011. [PubMed]
  9. Kang MH, Smith MA, Morton CL, Nino Keshelava N, Houghton PJ, Reynolds CP: National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (EPUB Oct, 2010). [PubMed]
  10. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger RC, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM: Anti-GD2 antibody with GM- CSF, IL2 and isotretinoin for neuroblastoma: A Children’s Oncology Group (COG) phase III study. New England J Medicine 363:1324-1333, 2010. (Faculty of 1000 ranked this paper in top 2% of biology and medicine published papers.) [PubMed]
  11. Kang MH, Wan Z, Kang YH, Locke RS, Reynolds CP: Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J National Cancer Institute 100:580-595, 2008. [PubMed]
  12. Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP: Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORB™ organized lipid complex in mice. Clinical Cancer Research 13:3079-3086, 2007. [PubMed]
  13. Villablanca JG, Krailo M, Ames MM, Bagniewski PG, Reid JM, Reynolds CP: A phase I trial of oral (capsular) fenretinide (NSC #374551) in children with high-risk solid tumors (Childrens Cancer Group Study 09709) J Clinical Oncology 24:3423-3430, 2006. [PubMed]
  14. Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Research 61:6185-6193, 2001. [PubMed]
  15. Maurer BJ, Cabot MC, Reynolds CP: Synergistic cytotxicity in solid tumor cell lines of N-(4-hydroxypheynl)- retinamide and modulators of ceramide metabolism. J National Cancer Institute 92:1897-1908, 2000. [PubMed]
  16. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shamada H, Black CG, Brodeur GM, Gerbing R, Reynolds CP: Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. New England J Medicine 341:1165-1173, 1999. [PubMed]
  17. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Research 58:5396-5405, 1998. [PubMed]
  18. Villablanca JG, Avramis V, Khan A, Matthay KK, Ramsay NKC, Seeger RC, Reynolds CP: Phase I trial of 13-cis- retinoic acid (cRA) in neuroblastoma patients following bone marrow transplantation (BMT). J Clinical Oncology 13:894-901, 1995. [PubMed]
  19. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG. Characterization of human neuroblastoma cell lines established before and after therapy. J National Cancer Institute 76:375 387, 1986. [PubMed]
  20. Thiele CJ, Reynolds CP, Israel MA: Decreased expression of N myc precedes retinoic acid induced morphological differentiation of human neuroblastoma. Nature 313:404 407, 1985. [PubMed]

History & Education

Degrees

1974 BA Biology - University of Texas at Austin
1979 MD University of Texas Southwestern Medical School, Dallas, TX
1979 PhD Cell Biology - University of Texas at Austin

Postdoctoral Research Fellowships

1980 University of Texas Southwestern Medical School, Dallas, TX

Residency

1981 Pediatrics, National Naval Medical Center, Bethesda, Maryland

Honors

1988 Gold Medal for Research Achievement awarded by Nihon University, Tokyo, Japan
1992 Team Physician, 1992 USA Olympic Shooting Team, 25th Olympiad, Barcelona, Spain
2004 Eurand Prize for Novel Approaches in Oral Drug Delivery by the Controlled Release Society
2008 Best Clinical Paper Award, Advances in Neuroblastoma Research, Chiba, Japan
2011 Most cited paper in Clinical Cancer Research, 2009
  (Clinical Cancer Research 15:1126-1132, 2009)
2011 TTU System Chancellor's Council Distinguished Research Award
2012 Covenant Health Systems David R. Close, MD Endowed Chair in Oncology

National and State Leadership and Advisory Positions

2000 - Present US FDA Pediatric Subcommittee of the Oncologic Drugs Advisory Committee
2007 - 2008 Natl. Cancer Inst. SBIR/STTR ZRG1 Cancer Drug Dev. + Therapeutics Study Section
2008 - Present Natl. Inst. Child Health and Development, Best Pharmaceuticals for Children Act Panel
2008 - 2013 Chartered member, Natl. Cancer Inst Drug Discovery + Molecular Pharm. Study Section
2009 - Present Advisory Committee on Childhood Cancer, Cancer Prevention Research Inst of Texas
2012 - Present FDA, NCI, NICHD BPCA Pediatric Oncology Working Group
2012 - 2014 University Advisory Committee, Cancer Prevention & Research Inst of Texas

Current Grant Support

Grants as Principal Investigator

NCI Contract Pediatric Preclinical Testing Program In Vitro Drug Testing Laboratory 11/04-10/14
CPRIT RP110763 Texas Cancer Cell Repository 06/11-12/14
St. Baldricks COG Clinical Trial Access 01/12-12/14
NCI R21 (CA161889) Phase 1 Trial of Fenretinide & Safingol 08/11-07/14

Grants as Co-Investigator

NCI RO1 CA168699 Kang, M (PI) Pharmacokinetics and Pharmacogenomics of 13-cis-RA in high-risk neuroblastoma 08/01/13-07/31/17
CPRIT RP130547 Kang, M (PI) Pharmacokinetics and Pharmacogenomics of 13-cis-RA in high-risk neuroblastoma 12/1/2013-11/30/2016
©